A Clinical Study Of Probucol On Carotid Artery Vulnerable Plaques

Objective:Comparison between the experimental group and the control group before and after treatment in carotid artery plaque detection rate and carotid artery intima-media thickness, as well as the treatment of events during the incidence of ischemic stroke, and evaluate the clinical effect of probucol treatment of carotid artery plaque.Methods:Selected100patients in our hospital in2012Octobert to2013June inpatient and outpatient patients, diagnosed by color ultrasound identified vulnerable carotid atheromatous plaque.Inclusion criteria:the exclusion of tumor, liver disease, infectious diseases, no major injury recently, operation history.In100patients (male79cases, female21cases, age41-75years old) were randomly divided into experimental group (n=50) and control group (n=50).Two groups of patients with basic treatment is basically the same, oral Aspirin Enteric-coated Tablets100mg,1times daily (Bayer healthcare Co. Ltd.), Atorvastatin Calcium Tablets20mg,1times a day (Pfizer Inc), selected according to the condition of patients with antihyperten-ive drugs, hypoglycemic therapy.In the experimental group, routine therapy plus probucol250mg,2times/day (Shandong Qilu Pharmaceutical Co., Ltd.,125per piece mg); drug therapy for6months.During treatment, not taking the drugs or other similar drugs for regulating blood lipid and antioxidant effects on atherosclerosis. Observed before and after treatment in the3months and6months after the experimental group and the control group were the original plaque thickness changes and carotid artery plaque detection rate.Before and after treatment were compared using the paired t test, count data using x2test. Using SPSS19statistical software for statistical analysis. P<0.05, the difference was statistically significant.Results:The two groups of patients before treatment of carotid artery plaque detection rate, are100%; carotid intima-media thickness before treatment, no significant difference (P>0.05). After3months of treatment:plaque of carotid artery in experimental group detection rate from100%before treatment to42%, control group, the detection rate of carotid plaques from100%before treatment to62%. The experimental group of vulnerable atherosclerotic plaque of carotid artery to stable plaque were significantly higher than those in the control group. X2=4.00, P<0.05, there is significant difference. The experimental group of vulnerable atherosclerotic plaque of carotid artery IMT before treatment was3.34±0.42mm,2.07±0.38mm after treatment, the control group vulnerable atherosclerotic plaque of carotid artery IMT before treatment was3.15±0.50mm,2.41±0.32mm after treatment. The two groups after treatment compared with the P<0.05, there was significant difference.After6months of treatment:plaque of carotid artery in experimental group detection rate from100%before treatment to6%, control group, the detection rate of carotid plaques from100%before treatment to20%. The experimental group of vulnerable atherosclerotic plaque of carotid artery to stable plaque were significantly higher than those in the control group. X2=4.33, P<0.05, there is significant difference.Comparison of two groups of patients with carotid artery IMT, the experimental group of vulnerable atherosclerotic plaque of carotid artery IMT was3.3.4±0.42mm before treatment, after treatment, the control group was1.29±0.51mm, carotid artery plaque IMT before treatment was3.15±0.50mm,1.63±0.37mm after treatment. Before treatment between the two groups in P>0.05, no significant differences between the two groups after treatment; comparison of P<0.05, there was significant difference.Conclusion:This test confirmed that probucol can inhibit oxidative stress, from the source block atherosclerosis, vulnerable plaque, and reduces plaque volume, inhibition of plaque progression, prevent plaque rupture and events. In the treatment of vulnerable plaques, antiplatelet therapy and statin therapy effect should be affirmed.